Recent advance in the discovery of allosteric inhibitors binding to the AMP site of fructose-1,6-bisphosphatase / 药学学报
Acta Pharmaceutica Sinica
;
(12): 1291-1300, 2011.
Artículo
en Chino
| WPRIM
| ID: wpr-232995
ABSTRACT
Fructose-1, 6-bisphosphatase (FBPase), a rate-limiting enzyme involved in the pathway of gluconeogenesis, can catalyze the hydrolysis of fructose-1, 6-bisphosphate to fructose-6-phosphate. Upon inhibiting the activity of FBPase, the production of endogenous glucose can be decreased and the level of blood glucose lowered. Therefore, inhibitors of FBPase are expected to be novel potential therapeutics for the treatment of type II diabetes. Recent research efforts were reviewed in the field of developing allosteric inhibitors interacting with the AMP binding site of FBPase.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Farmacología
/
Sitios de Unión
/
Sangre
/
Glucemia
/
Adenosina Monofosfato
/
Química
/
Fructosa-Bifosfatasa
/
Diabetes Mellitus Tipo 2
/
Inhibidores Enzimáticos
/
Sitio Alostérico
Límite:
Animales
/
Humanos
Idioma:
Chino
Revista:
Acta Pharmaceutica Sinica
Año:
2011
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS